AIP
SEEL

Ameritas Investment Partners’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Ameritas Investment Partners’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed -$5K – 3278
2022
Q1 		$5K Hold
2
– – ﹤0.01% 2977
2021
Q4 		$10K Hold
2
– – ﹤0.01% 2912
2021
Q3 		$14K Hold
2
– – ﹤0.01% 2854
2021
Q2 		$16K Buy
+2
New +$32.9K ﹤0.01% 2839

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Investment Partners's SEEL Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2022, closing a stake of 2 shares — an estimated $5K sold.

Ameritas Investment Partners first reported a position in SEEL in Q2 2021 and held it in 4 quarters. The position peaked at $16K in Q2 2021. 65 funds tracked by Wall St. Rank hold SEEL as of Q2 2022.

  • Ameritas Investment Partners reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 2 Seelos Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $5K.
  • Ameritas Investment Partners first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Ameritas Investment Partners's Seelos Therapeutics, Inc. Common Stock position peaked at $16K in Q2 2021.
  • 65 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.